Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for its Baddi manufacturing facility following an inspection conducted in August 2025. The USFDA has classified the facility as Voluntary Action Indicated (VAI) and concluded the inspection as closed. This signifies the successful completion of the inspection process and adherence to required standards at the Baddi facility.
Baddi Facility Receives EIR
Zydus Lifesciences announced that it has received the Establishment Inspection Report (EIR) from the USFDA for its manufacturing facility located in Baddi. The inspection was conducted from August 4th to August 13th, 2025.
Inspection Outcome
The USFDA has classified the Baddi facility as Voluntary Action Indicated (VAI), indicating that the agency will not take regulatory or administrative action. The USFDA has also concluded the inspection, marking the closure of the process.
Source: BSE
